Analysts expect Spero Therapeutics Inc (NASDAQ:SPRO) to post earnings per share (EPS) of ($0.88) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Spero Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.09) and the highest estimate coming in at ($0.67). The firm is scheduled to report its next earnings report on Thursday, August 9th.
On average, analysts expect that Spero Therapeutics will report full year earnings of ($3.33) per share for the current year, with EPS estimates ranging from ($3.95) to ($2.81). For the next financial year, analysts expect that the firm will post earnings of ($4.48) per share, with EPS estimates ranging from ($7.52) to ($3.30). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that cover Spero Therapeutics.
Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings data on Thursday, May 10th. The company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($1.20) by $0.46. The firm had revenue of $1.15 million for the quarter, compared to the consensus estimate of $0.20 million.
Several research firms recently commented on SPRO. Oppenheimer set a $30.00 price objective on shares of Spero Therapeutics and gave the stock a “buy” rating in a research note on Sunday, May 13th. Cantor Fitzgerald set a $27.00 price target on shares of Spero Therapeutics and gave the company a “buy” rating in a research note on Monday, April 30th. HC Wainwright initiated coverage on shares of Spero Therapeutics in a research note on Friday, May 11th. They set a “buy” rating and a $28.00 price target on the stock. ValuEngine upgraded shares of Spero Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Finally, Zacks Investment Research upgraded shares of Spero Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 21st. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $25.00.
A number of institutional investors have recently modified their holdings of the business. BVF Inc. IL increased its stake in Spero Therapeutics by 1.9% during the 1st quarter. BVF Inc. IL now owns 1,048,958 shares of the company’s stock valued at $14,948,000 after purchasing an additional 19,773 shares in the last quarter. Rock Springs Capital Management LP acquired a new position in Spero Therapeutics during the 4th quarter valued at approximately $6,169,000. VHCP Management II LLC acquired a new position in Spero Therapeutics during the 4th quarter valued at approximately $5,706,000. AWM Investment Company Inc. acquired a new position in Spero Therapeutics during the 4th quarter valued at approximately $4,112,000. Finally, JPMorgan Chase & Co. increased its stake in Spero Therapeutics by 19,604.3% during the 1st quarter. JPMorgan Chase & Co. now owns 256,353 shares of the company’s stock valued at $3,653,000 after purchasing an additional 255,052 shares in the last quarter. Institutional investors and hedge funds own 45.90% of the company’s stock.
NASDAQ SPRO opened at $14.50 on Thursday. The company has a market cap of $163.66 million and a P/E ratio of -0.81. Spero Therapeutics has a 52 week low of $9.66 and a 52 week high of $19.00.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.
Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.